Just days after winning FTC approval to take on three of Catalent’s facilities, Novo Nordisk said it is investing DKK 8.5 ...

Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with ...

FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...

Endpoints Weekly covers ASH conference highlights, FDA discussions on Moderna's RSV vaccine safety, Biosecure Act exclusion, and industry updates from biotech leaders.

Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.

The FDA is pushing back against claims that its safety restrictions for the abortion pill mifepristone are “onerous and ...

Bicycle Therapeutics reports mixed data for zelenectide pevedotin in cancer trials, with 60% response rate in urothelial ...

The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday ...

BeiGene acquires MTAP deletion drug SYH2039 from CSPC for $150M, plans combo with BGB-58067, competing with Ideaya's IDE397 ...

Boundless Bio is trimming its oncology pipeline in the wake of disappointing cancer data and switching up its leadership just ...

San Antonio Breast Cancer Conference featured updates on VEGF bispecifics, oral protein degraders, and data from BeiGene, ...

Repare Therapeutics announced that a combination of two targeted drugs resulted in confirmed responses of 19% and 17% in ...